As Cell Therapy Approvals Speed Up, Companies Struggle with Manufacturing Demands

Biostorage: A Critical Component of the Medical Research Development Process

When Failure Isn’t an Option, Trust the Supply Chain Partners with a Proven and Successful Track Record

Scientific Innovation is Messy. Cryoport is The Reliable Logistics Provider for the Cell and Gene Therapy Trial Process

Cell and Gene Therapy Success Depends on Mastering the New Needs of the Supply Chain: Dispatch from the Shanghai CAR-T Summit

Growing with Our Clients: New Cryoport Innovations Help Support Commercial Gene Therapies and Nearly 400 Clinical Trials

With More Than 200 Cell and Gene INDs on File with FDA by 2020, Challenges Lie Ahead on Path to Approval

Cryoport Rings Nasdaq Closing Bell

As the Regenerative Medicine Industry Grows, A Complete Support System Is More Critical Than Ever

Learn About Cryoport’s Latest Innovations at the 2019 World Advanced Therapies and Regenerative Medicine Congress and Expo in London

Unpacking the Physics of Cryoport’s Certified, Cool 2-8°C Shipper for Fresh Biospecimen Transportation

What’s Next For Regenerative Medicine: Regulations—Lots of Regulations

Can you Afford to Not Consider the Importance of Informatics in Your Global Temperature Controlled Supply Chain?

Risk Mitigation in Clinical Trials

Why "Wait and See" Isn't an Option

Shipping Validations are Common Shipping New Pharmaceutical Products - But Who ‘Validates’ the Carriers? Cryoport Can!

Ensure Chain of Compliance™ in Your Supply Chain

How to Prevent Damage to Biomaterials During Shipment

FDA’s Recent Outlook and New Policies for Cell and Gene Therapies

Why Evaporative Cooling Shippers Are Not Optimal for Pharmaceutical Applications in the 2-8°C Range

Can You Ship Biological Samples Currently Stored or Shipped with Dry Ice (-0 to -80°C) in Cryoport’s Dry Vapor Shipper at -150°C?

What Do You Know About Your Dry Vapor Shipper and its Potential Impact on your Critical Materials?

The Critical Need for the End to End Data Flows for Regenerative Therapies

Beyond Logistics – What’s Needed for Successful Support of Clinical Trials and Commercialization in Regenerative Medicine?

Transportation Safety: Same and Different Across Countries

The Emergence of Chain of Compliance™

Are You Securing “Smooth” Compliant Movement of Your Biological Materials?

Compliance Considerations Driving Temperature-Controlled Logistics

Cryoport’s Temperature Controlled Logistics Solutions Supporting Regenerative Medicine Advanced Therapy (RMAT) Clinical Development

Scientific Conclusions Are All About the Data--Choosing a Logistics Provider For Biomaterial Transport Should Be As Well

Considerations for Successful Biomaterial Transport into Challenging Countries

Transporting Life: A Journey of Choice

Dry Vapor: The Hero for the Ever-Growing CO2 Shortage

Cryoport is the Complete Logistics Solution for Your Clinical Programs

Cryoport Practices Quality by Design (QbD) Approaches When Developing New Products and Processes

Cancer MoonShot 2020 Initiative Spurs Immunotherapy Research and Integrated Logistics Need

Cold Chain Solutions for Autologous Cell Therapy Commercialization

Using Real-World Data to Reduce Cold Chain Risk

Outsourcing Dewar Management to Improve Human and Animal Health Operations

Cryoport Now Supports Laboratory Relocation

Helping Hospitals Unmask Cancer

Notes From The Field – Minimizing Cold Chain Risk for Regenerative Medicines

Cryoport Allows Yancey Farms to Meet Peak Demand During Breeding Season

The Top 5 Hidden Costs of Dry Ice Shipping

Cryoport, the Company Behind the Technology used in the FedEx® Deep Frozen Shipping Solution